Wang Y, Klein JD, Liedtke CM, Sands JM. Protein kinase C regulates urea permeability in the rat inner medullary collecting duct. Am J Physiol Renal Physiol 299: F1401-F1406, 2010. First published September 22, 2010 doi:10.1152/ajprenal.00322.2010.-Hypertonicity increases urea transport independently of, as well as synergistically with, vasopressin in the inner medullary collect duct (IMCD). We previously showed that hypertonicity does not increase the level of cAMP in the IMCD, but it does increase the level of intracellular calcium. Since we also showed that hypertonicity increases both the phosphorylation and biotinylation of the urea transporters UT-A1 and UT-A3, this would suggest involvement of a calcium-dependent protein kinase in the regulation of urea transport in the inner medulla. In this study, we investigated whether protein kinase C (PKC), which is present in the IMCD, is a regulator of urea permeability. We tested the effect of PKC inhibitors and activators on urea permeability in the isolated, perfused rat terminal IMCD. Increasing osmolality from 290 to 690 mosmol/kgH2O significantly stimulated (doubled) urea permeability; it returned to control levels on inhibition of PKC with either 10 M chelerythrine or 50 M rottlerin. To determine the potential synergy between vasopressin and PKC, phorbol dibutyrate (PDBu) was used to stimulate PKC. Vasopressin stimulated urea permeability 247%. Although PDBu alone did not change basal urea permeability, in the presence of vasopressin, it significantly increased urea permeability an additional 92%. The vasopressin and PDBu-stimulated urea permeability was reduced to AVP alone levels by inhibition of PKC. We conclude that hypertonicity stimulates urea transport through a PKC-mediated phosphorylation. Whether PKC directly phosphorylates UT-A1 and/or UT-A3 or phosphorylates it as a consequence of a cascade of activations remains to be determined. tubule perfusion; calcium signaling; urine concentration; vasopressin; hypertonicity UREA AND UREA TRANSPORTERS (UT) are crucial for the urinary concentrating mechanism. Since the first observation that urea is important in the control of water homeostasis by Gamble et al. in 1934 (6), many studies have reported the integral role of urea in the production of a concentrated urine. Early studies looked at the effect of varying the protein level in the diets of animals and people (5, 6, 12) . The most rigorous method of assessing urea transport is to perform ex vivo perfusion studies to directly measure the movement of urea across the inner medullary collecting duct (IMCD). Tubule perfusion studies established that there are UT involved in the movement of urea through the IMCD cells (20). The transporters perform at both basal and stimulated levels. The regulation of these transporters is an important determinant in the permeability of the IMCD to urea. Studies show that urea permeability can be affected by vasopressin, angiotensin II, calcium, steroid hormones, and changes in tonicity (8, 14, 20, 21) .
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One of the earliest observations made using tubule perfusion studies was that vasopressin is the primary hormone that regulates urea permeability in the IMCD (20, 24) . Vasopressin binds to the V 2 receptors on the basolateral plasma membrane of the IMCD, which results in stimulation of adenylyl cyclase and generation of cAMP. cAMP stimulates two downstream signals: protein kinase A and exchange protein activated by cAMP (25) , thereby resulting in an increase in urea permeability.
Vasopressin stimulation of urea permeability is due, in large part, to the stimulation of the UT-A1 and UT-A3 urea transporters in the IMCD (14) . These urea transporters are members of the SLC14A2 family. UT-A1 is the largest of the urea transporters and is located at the apical plasma membrane of the IMCD. UT-A3 is essentially the NH 2 -terminal half of UT-A1 and is located at the basolateral plasma membrane of the IMCD (18) . UT-A3 is also present in the apical plasma membrane when the animal has been treated with vasopressin, suggesting that UT-A3, as well as UT-A1, is regulated by vasopressin (3). The mechanism for vasopressin's regulation involves vasopressin-stimulated increases in both the phosphorylation and apical plasma membrane accumulation of the UT-A1 urea transporter (3, 4, 27) .
Vasopressin is not the only regulatory stimulus for urea transport, however. Several studies show that urea permeability in isolated, perfused IMCDs is also activated by hypertonicity (adding NaCl or mannitol) in the absence of vasopressin (7, 15, 21) . Increasing osmolality in the presence of vasopressin produces an additive effect on urea permeability (7, 15, 21) . Unlike vasopressin, hypertonicity increases intracellular calcium, but does not change cAMP accumulation (8) . These findings indicate that hypertonicity is an independent activator of urea transport, and it acts through intracellular calcium instead of cAMP. Hypertonicity increases the phosphorylation and plasma membrane accumulation of UT-A1 and UT-A3, which may result in an increase in urea permeability (2) . The manner by which hypertonicity stimulates the urea transporters or urea permeability is not yet understood.
The present study extends information about PKC signaling on urea permeability. We first determined whether PKC is involved in hypertonicity-stimulated urea permeability. The primary rationale for performing this aspect of our study is that hypertonicity increases urea permeability via changes in intracellular calcium, suggesting involvement of a calcium-dependent protein kinase in the urea transport response. Next, we explored the mechanisms for PKC regulation and tested the hypothesis that PKC synergistically works with cAMP to stimulate urea permeability.
METHODS

Animals.
All animal protocols were approved by the Emory University Institutional Animal Care and Use Committee. Male SpragueDawley rats (Charles River Laboratories, Wilmington, MA), weighing 50 -75 g, were injected with furosemide (5 mg/kg body wt) 30 min before death. Kidneys were dissected to remove inner medullas. Single tubules from the terminal IMCD were microdissected at 17°C.
Tubule perfusion. Single IMCDs were dissected, mounted on glass pipettes, and perfused as described previously (19, 20) . In general, 45 min after the tubules were warmed to 37°C in 1 ml of bath solution, three 1-min collections of 30 -50 nl/min were made.
To measure the response to treatments, buffers were changed or treatments were added to the bath, tubules were allowed to equilibrate for 15 min, then three further collections were made, and urea was assessed using ultramicrofluorometry. Urea permeability was calculated as described previously (19, 20) .
To subject the tubules to hypertonic conditions, the osmolalities of both the perfusate and the bath were increased from 290 to 690 mosmol/kgH 2O by adding 200 mM NaCl. To assess the contribution of PKC, cell-permeable PKC inhibitors (10 M chelerythrine or 50 M rottlerin) were added to the bath. Alternatively, the PKC stimulator phorbol-dibutyrate (PDBu; 200 nM) was added to the bath.
To test for synergistic effects of cAMP and PKC on urea permeability, basal urea permeability was measured followed by sequential addition of vasopressin and PDBu. First, 200 pM vasopressin was added to the bath and urea permeability was measured. Next, 200 nM PDBu was added to the bath in the presence of vasopressin, and urea permeability was measured. In an additional approach, both 200 pM vasopressin and 200 nM PDBu were added simultaneously to the bath 45 min after the tubule was warmed to 37°C. After 15 min, urea permeability was measured. To verify that the effects observed with simultaneous PDBu/vasopressin treatment were due to PKC, 10 M chelerythrine was added to the bath, and urea permeability was measured.
Western blot analysis. Identical samples of whole inner medullary protein lysate (20 g/lane) were size separated by SDS-PAGE on 10% gels and then electroblotted to polyvinylidene difluoride membranes (Immobilon, Millipore, Bedford, MA). Blots were blocked with 5% nonfat dry milk in Tris-buffered saline (20 mM Tris·HCl, 0.5 M NaCl, pH 7.5) and then incubated with primary antibodies overnight at 4°C. Attached primary antibodies were identified using Alexa Fluor 680-linked anti-rabbit IgG (Molecular Probes, Eugene, OR) and visualized using infrared detection with the LICOR Odyssey protein analysis system (Lincoln, NE). Antibodies to PKC ␣, ␤, ␦, ␥, , , and were purchased from Cell Signaling Technology (Danvers, MA).
Statistics. All data are presented as means Ϯ SE. Data from tubule perfusion studies were analyzed using a paired Student's t-test or repeated-measures ANOVA, depending on whether two conditions or more than two conditions were assessed in each tubule (22) . Each tubule serves as its own control, allowing a paired analysis of the data. The criterion for statistical significance is P Ͻ 0.05.
RESULTS
Urea permeability in hypertonic conditions. Increasing the osmolality of the perfusate and bath solutions from 290 to 690 mosmol/kgH 2 O resulted in a significant increase in urea permeability from 24 Ϯ 2 to 49 Ϯ 4 ϫ 10 Ϫ5 cm/s (n ϭ 4, P Ͻ 0.01; Fig. 1A ). The increased urea permeability was significantly reduced to 30 Ϯ 3 ϫ 10 Ϫ5 cm/s by addition of the PKC inhibitor chelerythrine (10 M) to the hypertonic bath solution (n ϭ 4, P Ͻ 0.01; Fig. 1A ). The bar graph in Fig. 1B shows the urea permeabilities as a percent of control levels. Hypertonicity increased urea permeability to 208% of the level in isotonic conditions. Urea permeability was returned to nearly control levels (129%) by inhibition of PKC with chelerythrine.
To further confirm the role of PKC in the regulation of urea permeability, 50 M rottlerin (a second chemical inhibitor of PKC that inhibits a wide spectrum of PKCs at 50 M) was added to the hypertonic bath. As before, hypertonicity increased urea permeability from 23 Ϯ 2 to 43 Ϯ 3 ϫ 10 Ϫ5 cm/s (n ϭ 4, P Ͻ 0.01; Fig. 2A ). Addition of rottlerin significantly decreased urea permeability to 21 Ϯ 2 ϫ 10 Ϫ5 cm/s (n ϭ 4, P Ͻ 0.01; Fig. 2A ). The changes in permeability as percent of control are presented in bar graph form in Fig. 2B . Hypertonicity increased urea permeability by 191%. Urea permeability was returned to nearly control levels (90%) by inhibition of PKC with rottlerin.
Urea permeability stimulated by PDBu. To verify the effects of the PKC inhibitors, we measured urea permeability when PKC was stimulated using a phorbol ester, PDBu (200 nM), which is known to stimulate the regulatory domain of PKC (16) . The urea permeability after PDBu treatment (32 Ϯ 3 ϫ 10 Ϫ5 cm/s) was not different from basal urea permeability (29 Ϯ 1 ϫ 10 Ϫ5 cm/s, n ϭ 4). Three approaches were designed to test for synergistic effects of PDBu and vasopressin. First, urea permeabilities were assessed under conditions where vasopressin-stimulated IMCDs were then treated with a PKC stimulant. Figure 3 shows this approach. Vasopressin significantly increased urea permeability from 21 Ϯ 2 to 74 Ϯ 16 ϫ 10 Ϫ5 cm/s (n ϭ 6, P Ͻ 0.05; Fig. 3A ). Subsequent addition of 200 nM PDBu to the bath (to stimulate PKC with vasopressin present) further increased urea permeability to 94 Ϯ 18 ϫ 10 Ϫ5 cm/s (n ϭ 5, P Ͻ 0.05; Fig. 3A) . The changes in permeability as percent of control are presented in bar graph form in Fig. 3B . Vasopressin increased urea permeability from 100% (basal control) to 347%. Urea permeability was further increased to 439% by stimulation of PKC with PDBu. We also performed the time control experiment where vasopressin was added after the initial 45-min warming period (basal readings), and urea permeability was monitored periodically over an additional 45 min. Within 15 min following addition of vasopressin to the bath, urea permeability increased from 15 Ϯ 1 to 60 Ϯ 7 ϫ 10 Ϫ5 cm/s, where it was maintained for an additional 30 min (data not shown).
The second approach was to stimulate urea permeability by adding vasopressin and PDBu together, and then assess whether inhibition of PKC removed the stimulation of urea permeability. The tubules were treated initially with both 200 pM vasopressin and 200 nM PDBu and urea permeability was measured (80 Ϯ 8 ϫ 10 Ϫ5 cm/s, n ϭ 4; Fig. 4A ). To verify that the effects observed with simultaneous PDBu/ vasopressin treatment include a PKC-mediated stimulation, 10 M chelerythrine was added to the bath. Urea permeability significantly decreased to 58 Ϯ 6 ϫ 10 Ϫ5 cm/s (n ϭ 4, P Ͻ 0.01 by paired t-test; Fig. 4A ). The changes in permeability as percent of control are presented in bar graph form in Fig. 4B . Chelerythrine decreased urea permeability from 100% (vasopressinϩPDBu control) to 72%. To ensure that the changes observed with chelerythrine were not due to the prolonged exposure to PDBu, we performed a time control in which PDBu and vasopressin were both present in both periods. Urea permeability was 72 Ϯ 7 ϫ 10 Ϫ5 cm/s in period 1 and showed a slight increase to 84 Ϯ 4 ϫ 10 Ϫ5 cm/s in period 2 (n ϭ 3, P ϭ NS).
The third approach to determining the potential synergy between vasopressin and PKC was to determine whether inhibition of PKC would block the action of PDBu on urea permeability. To ensure that chelerythrine was inhibiting by blocking PKC and not directly affecting vasopressin-mediated urea permeability, tubules were first treated with 200 pM vasopressin, then incubated with 10 M chelerythrine, and finally treated with 200 nM PDBu. Chelerythrine significantly decreased urea permeability from 61 Ϯ 6 to 53 Ϯ 7 ϫ 10 Ϫ5 cm/s in the IMCDs initially treated with 200 pM vasopressin alone (n ϭ 4, P Ͻ 0.05; Fig. 5A ). Subsequent addition of 200 Fig. 2 . Hypertonicity-induced increase in urea permeability was reversed by inhibition of protein kinase C (PKC) with rottlerin (Rott). A: terminal IMCDs were perfused with isotonic buffer (290 mosmol/kgH2O), then switched to hypertonic buffer (690 mosmol/ kgH2O), and then supplemented with 50 M Rott. Each line represents a separate IMCD from a different rat. B: bar graph showing the percent change from isotonic control levels. Bars ϭ means Ϯ SE. *P Ͻ 0.01 vs. 290 mosmol/kgH2O; #P Ͻ 0.01 vs. 690 mosmol/kgH2O without inhibitor; n ϭ 4 rats/condition. nM PDBu (with vasopressin and chelerythrine present) to the bath did not increase the urea permeability. Instead, urea permeability continued to decrease to 43 Ϯ 6 ϫ 10 Ϫ5 cm/s (n ϭ 4, P Ͻ 0.01; Fig. 5A ). The changes in urea permeability as percent of control are presented in bar graph form in Fig. 5B . Urea permeability was decreased from 100% (vasopressin control) to 87% by addition of chelerythrine, and continued to decrease to 71% during the 15 min after addition of PDBu.
To ensure that the decrease in urea permeability was not due to an effect of the PKC inhibitor that was greater during the third compared with the second set of collections, we performed a time control in which PDBu and vasopressin were both present in periods 2 and 3. Urea permeability was 84 Ϯ 4 ϫ 10 Ϫ5 cm/s in period 2 and 90 Ϯ 2 ϫ 10 Ϫ5 cm/s in period 3 (n ϭ 3, P ϭ NS).
Effect of PKC inhibition under isotonic conditions. To examine the effect of PKC antagonists on urea permeability in the absence of hypertonicity, we perfused tubules using isotonic (290 mosmol/kgH 2 O) solutions. The PKC inhibitor chelerythrine (10 M) did not change urea permeability (basal: 15 Ϯ 1, chelerythrine: 12 Ϯ 1 ϫ 10 Ϫ5 cm/s, n ϭ 3, P ϭ NS; Fig. 6A ). Subsequent addition of vasopressin (200 pM) with chelerythrine still present did not change urea permeability (13 Ϯ 1 ϫ 10 Ϫ5 cm/s, n ϭ 3, P ϭ NS; Fig. 6B ).
PKC isoforms in kidney inner medulla.
The identity of the PKC isoform that is involved in the increase of urea permeability in the inner medulla is unknown. There are several PKC isoforms that are expressed in the inner medulla (Fig. 7) including conventional PKC isoforms that are responsive to calcium and diacylglycerol (PKC␣, PKC␤, and PKC␥), as well as novel isoforms (PKC␦, PKCε, PKC, and PKC) which are calcium independent, and the atypical isoform, PKC. Of these, both conventional and novel PKC isoforms are responsive to phorbol ester activation and thus would be potential activators of urea permeability in the inner medulla.
DISCUSSION
It is well-established that urea permeability is regulated by vasopressin via cAMP-dependent signaling pathways. This study provides evidence that hypertonicity increases urea permeability through a PKC-signaling pathway. In addition, direct activation of PKC by a phorbol ester, PDBu, requires the synergy of vasopressin to stimulate urea permeability. Together with findings from previous studies (14, 27) , the present study suggests that maximal increases in urea transport in rat terminal IMCDs require stimulation of both cAMP and PKCsignaling pathways. Previous studies show that hypertonicity increases urea permeability (21) and plasma membrane accumulation of both UT-A1 and UT-A3 in rat terminal IMCDs (2) . The responses to hypertonicity occur through increases in intracellular calcium and activation of PKC has been suggested to play a role (8, 14) . To determine the role of PKC in hypertonicity-stimulated urea permeability, hypertonicity (690 mosmol/kgH 2 O) was used as a means to stimulate PKC in the present study. Our data show that hypertonicity significantly increases urea permeability ( Figs. 1 and 2) , which is consistent with a previous study (21) . To verify that the increase in urea permeability is in response to activation of PKC, two PKC inhibitors, chelerythrine and rottlerin, were used to decrease urea permeability. Chelerythrine acts on the catalytic domain of PKC and is a broad-type inhibitor of PKC. Rottlerin is a PKC␦-specific inhibitor. However, at the higher concentration (50 M) used in this study, rottlerin also inhibits a broad spectrum of PKC isoforms, including PKC␣, PKC␤, PKC␥, and PKC, and PKCε, PKC, and PKC with a reduced inhibitory activity (9 -11, 23) . The data in the present study show that both PKC inhibitors reversed the increase by hypertonicity to nearly basal levels of urea permeability ( Figs. 1 and 2 ), which strongly supports the concept that hypertonicity increases urea permeability by stimulating PKC.
To understand the mechanism by which the PKC pathway regulates urea permeability, we also used the phorbol ester PDBu to directly stimulate PKC. PDBu binds to the regulatory domain of PKC and thereby activates it (16) . The present study shows that PDBu alone does not change urea permeability. However, PDBu significantly increased vasopressin-stimulated urea permeability (Fig. 3 ). These data suggest that an interaction between vasopressin and PKC is necessary for PKC to stimulate urea permeability.
Angiotensin II has been shown to exert its effects through PKC-mediated pathways. Liu and Cogan (17) showed that PKC may be involved in as much as one-third of the angiotensin II-stimulated bicarbonate and water transport in the S1 and S2 segments of the proximal tubule. Amlal et al. (1) reported that a high concentration (Ն5 ϫ 10 Ϫ11 M) of angiotensin II stimulates Na
ϩ -2Cl Ϫ cotransport via PKC in the medullary thick ascending limb. In rat IMCDs, angiotensin II significantly increases urea permeability above vasopressin-stimulated levels (14) , similar to the effects observed in the present study for PDBu. Angiotensin II has also been shown to increase UT-A1 phosphorylation in rat IMCD suspensions (14) . The angiotensin II-mediated increases in function and phosphorylation can be blocked by a PKC inhibitor (14) , suggesting a role for PKC-mediated signaling in the regulation of urea transport.
Interestingly, our previous data showed that angiotensin II alone, which can activate PKC in several renal tubule segments (1, 17) , had no effect on basal (no added vasopressin) urea permeability (14) . However, angiotensin II significantly increased vasopressin-stimulated urea permeability (14) . The comparable pattern of regulation by PDBu and by angiotensin II adds more credence to the hypothesis that PKC is involved in regulation of urea permeability by supplementing or enhancing vasopressin-stimulated urea permeability. The increase in urea permeability observed with simultaneous PDBu/vasopressin treatment was significantly reversed by chelerythrine, con- . Seven PKC isoforms are present in rat inner medulla. Lysate from whole rat inner medulla was analyzed by Western blot using PKC isoform-specific antibodies. An arrow identifies the PKC protein bands. sistent with PKC-mediated stimulation (Fig. 4) . Finally, after PKC was blocked with chelerythrine, PDBu treatment did not increase vasopressin-stimulated urea permeability (Fig. 5) . The agreement of the inhibitor and stimulator results strongly supports the idea of an interaction between vasopressin and PKC.
Recently, Yano et al. (26) demonstrated that glucagon reduces urea permeability and UT-A1 expression via a glucagon receptor and by stimulating PKC with phorbol myristate. This differs from our finding where stimulating PKC with PDBu had no effect on basal urea permeability. Their finding also differs from Isozaki et al. (13) who found no effect of glucacon on urea permeability. We do not have an explanation for these differences, but possibilities include the use of different rat strains ( We do not know why hypertonicity independently initiates PKC activation in the absence of overt vasopressin stimulation. It is possible that it only requires the endogenous vasopressin level to support the action of PKC in response to hypertonicity. In light of this hypertonic response, it is unclear why stimulation of PKC with PDBu or angiotensin II (14) does not show any stimulation of urea permeability in the absence of additional exogenous vasopressin. Perhaps hypertonicity activates different PKC isoform(s) than PDBu or angiotensin II, is a better activator, or stimulates additional signaling pathways? Further studies are needed to test these possible mechanisms. Clearly, however, in the presence of vasopressin, PDBu stimulation of PKC causes a significant increase in urea permeability.
In conclusion, the findings from the present study show that PKC regulates urea permeability in conjunction with vasopressin. These findings are likely to be physiologically significant. During antidiuresis, the inner medulla is often quite hypertonic. Under antidiuretic conditions, therefore, the increase in tonicity may be instrumental in increasing urea permeability through PKC-signaling pathways, in addition to the actions of vasopressin. We conclude that maximal stimulation of urea permeability in rat terminal IMCDs requires stimulation by both cAMP and PKC. Whether PKC directly phosphorylates UT-A1 and/or UT-A3, or phosphorylates as a consequence of a cascade of activations, remains to be determined.
GRANTS
